Biotech giant Regeneron announced Monday that it would acquire DNA testing company 23andMe for $256 million following a bankruptcy auction. The deal includes access to 23andMe's massive personal and genetic data trove from more than 15 million customers.

In its announcement of the acquisition, Regeron claimed it would ensure that customers’ personal data including genetic and health information, genealogy, and other sensitive personal information—would be safe and in good hands.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday.